SEOVF (Sernova Biotherapeutics) Gross-Profit-to-Asset % : 0.00% (As of Jan. 2025)

View and export this data going back to 1998. Start your Free Trial

What is Sernova Biotherapeutics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Sernova Biotherapeutics's annualized Gross Profit for the quarter that ended in Jan. 2025 was $0.00 Mil. Sernova Biotherapeutics's average Total Assets over the quarter that ended in Jan. 2025 was $3.81 Mil. Therefore, Sernova Biotherapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Jan. 2025 was 0.00%.

Sernova Biotherapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for Sernova Biotherapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Biotherapeutics Gross-Profit-to-Asset % Chart

Sernova Biotherapeutics Annual Data

Trend

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

Sernova Biotherapeutics Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Sernova Biotherapeutics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Sernova Biotherapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sernova Biotherapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sernova Biotherapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Sernova Biotherapeutics's Gross-Profit-to-Asset % falls into.

Save Embed

Sernova Biotherapeutics Gross-Profit-to-Asset % Calculation

Sernova Biotherapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Oct. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Oct. 2024 )	/	( (Total Assets (A: Oct. 2023 )	+	Total Assets (A: Oct. 2024 ))	/ count )
	=	0	/	( (16.122	+	5.471)	/ 2 )
	=	0	/	10.7965
	=	0.00 %

Sernova Biotherapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Jan. 2025 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jan. 2025 )	/	( (Total Assets (Q: Oct. 2024 )	+	Total Assets (Q: Jan. 2025 ))	/ count )
	=	0	/	( (5.471	+	2.139)	/ 2 )
	=	0	/	3.805
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Jan. 2025) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Sernova Biotherapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Sernova Biotherapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sernova Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Biotherapeutics Inc (OTCPK:SEOVF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

PSH0:Germany PSH0:Germany PSH0:Germany SVA:Canada

Address

700 Collip Circle, Suite 114, London, ON, CAN, N6G 4X8

Website

https://www.sernova.com

Sernova Biotherapeutics Inc is a clinical-stage company developing regenerative medicines. The company develops Cell Pouch with human donor cells or stem cells to create a biohybrid organ. The Cell Pouch is a implantable medical device designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells, which then release proteins, hormones, or other factors into the bloodstream for the long-term treatment of multiple chronic diseases such as type 1 diabetes, hypothyroid disease, and rare diseases such as hemophilia A.